Welcome to our dedicated page for Synlogic SEC filings (Ticker: SYBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding lab notes. Synlogic’s 10-K alone blends metabolic pathways, clinical trial statistics, and liquidity warnings—all essential yet painfully dense. Stock Titan surfaces what matters the moment it hits EDGAR.
Need the "Synlogic quarterly earnings report 10-Q filing"? It’s here, auto-tagged, with AI-powered summaries that strip away jargon. Curious about "Synlogic insider trading Form 4 transactions" before the next catalyst read-out? Our dashboard delivers "Synlogic Form 4 insider transactions real-time", complete with context on each executive’s role in the synthetic-biotics pipeline.
Every filing type is covered and decoded:
- 10-K / 10-Q: Track R&D spend, cash runway, and pipeline updates—"Synlogic annual report 10-K simplified".
- 8-K: From FDA feedback to partnership news—"Synlogic 8-K material events explained".
- Form 4: Monitor "Synlogic executive stock transactions Form 4" to spot insider confidence.
- DEF 14A: Drill into "Synlogic proxy statement executive compensation" without scrolling hundreds of pages.
Our AI doesn’t just summarize; it answers the questions you type—"understanding Synlogic SEC documents with AI" or "Synlogic earnings report filing analysis"—so you can decide whether a new trial milestone truly shifts valuation. Real-time alerts, full historical archives, and plain-English explanations mean one thing: complex synthetic-biotics disclosures, finally clear.
Synlogic, Inc. (SYBX) filed a shelf registration on Form S-3 to offer up to $150,000,000 of securities, including common stock, preferred stock, debt and warrants. The company reported that it discontinued Synpheny-3, the pivotal Phase 3 study of its lead candidate labafenogene marselecobac (SYNB1934), in February 2024 after an internal review indicated the trial was unlikely to meet its primary endpoint, and stated the decision was not based on safety or tolerability concerns.
Management says its strategy now prioritizes strategic alternatives to enhance stockholder value, including a potential merger or sale, while earlier-stage programs remain in development, notably SYNB1353 which achieved proof of mechanism in a Phase 1 study. The prospectus notes the common stock trades on Nasdaq under SYBX, with 11,698,919 shares outstanding as of August 6, 2025 and a last reported sale price of $1.39 on August 7, 2025.
FAQ
What is the current stock price of Synlogic (SYBX)?
What is the market cap of Synlogic (SYBX)?
